KER-012
Pulmonary Arterial Hypertension (PAH)
Key Facts
About Keros Therapeutics
Keros Therapeutics is focused on discovering and developing innovative treatments for patients with serious diseases by modulating the signaling pathways of the TGF-β protein superfamily. The company leverages its deep understanding of TGF-β biology to develop protein therapeutics that aim to correct imbalances in these pathways, which are implicated in hematopoiesis, muscle regeneration, and bone formation. Its pipeline includes multiple investigational candidates targeting conditions like anemia, pulmonary arterial hypertension, and muscle atrophy. Keros has advanced its lead asset into mid-stage clinical trials and has built a robust discovery platform to generate additional novel therapies.
View full company profileAbout Keros Therapeutics
Keros Therapeutics is focused on discovering and developing innovative treatments for patients with serious diseases by modulating the signaling pathways of the TGF-β protein superfamily. The company leverages its deep understanding of TGF-β biology to develop protein therapeutics that aim to correct imbalances in these pathways, which are implicated in hematopoiesis, muscle regeneration, and bone formation. Its pipeline includes multiple investigational candidates targeting conditions like anemia, pulmonary arterial hypertension, and muscle atrophy. Keros has advanced its lead asset into mid-stage clinical trials and has built a robust discovery platform to generate additional novel therapies.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| ANPA-0073 | Structure Therapeutics | Preclinical |
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia Corporation | Approved (Tentative) |
| LIQ861 (treprostinil) inhalation powder | Liquidia Corporation | Phase 3 |
| CS1 | Cereno Scientific | Phase II |
| Seralutinib | Gossamer Bio | Phase 3 |
| NTP42 | ATXA Therapeutics | Phase 1 |